Related Experiment Video
Updated: Aug 10, 2026
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
[What is the value of recent molecular biology knowledge for surgical oncologic therapy of soft tissue sarcoma?]
1Chirurgische Universitätsklinik Heidelberg.
Abstract:
While clinical progress in the treatment of soft-tissue sarcoma is rather slow, some major contributions to the understanding of oncogenesis of these rare tumors have been achieved in the last decade. The central role of cell cycle regulation has been demonstrated in hereditary (p53, RB) and somatic mutations or variant expression of genes associated with cell cycle regulation (p53, BCL2, MDM2). For a subset of soft tissue sarcomas harboring chromosomal translocations, fusion genes resulting from these specific translocations were cloned and characterized. The clinical use of these fusion genes may not be restricted to diagnosis and prognosis, since these may serve as specific targets for molecular and immunologic therapy approaches.
Insights
Understanding soft-tissue sarcoma oncogenesis has advanced, revealing cell cycle regulation
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Context:
- Soft-tissue sarcomas are rare tumors with slow clinical progress.
- Recent research has significantly advanced understanding of sarcoma oncogenesis.
- Key genes like p53, RB, BCL2, and MDM2 are implicated in cell cycle regulation.
Purpose:
- To summarize recent advancements in understanding soft-tissue sarcoma oncogenesis.
- To highlight the role of cell cycle regulation in sarcoma development.
- To explore the potential of fusion genes in diagnosis, prognosis, and therapy.
Summary:
- Cell cycle regulation plays a central role in soft-tissue sarcoma development, involving hereditary and somatic mutations in genes such as p53, RB, BCL2, and MDM2.
- Chromosomal translocations in a subset of sarcomas lead to specific fusion genes.
- These fusion genes are crucial for diagnosis and prognosis and represent potential therapeutic targets.
Impact:
- Advances in understanding sarcoma oncogenesis can lead to improved diagnostic and prognostic tools.
- Identification of fusion genes opens avenues for targeted molecular and immunologic therapies.
- This knowledge may accelerate clinical progress in soft-tissue sarcoma treatment.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...